US4778794A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical composition for the treatment of infantile autism
Assignee: Asubio Pharma Co Ltd
•
Filing: 1986-06-04
•
Granted: 1988-10-18
•
Expires: 2006-06-04
Abstract
Abstract A pharmaceutical composition for the treatment of infantile autism which contains tetrahydrobiopterin or a derivative thereof as a major effective ingredient and 5-hydroxytryptophan and/or L-DOPA as an optional auxiliary effective ingredient is provided.
Inventors
- 👤 Hiroshi Naruse
- 👤 Masashi Takesada
- 👤 Osamu Hayaishi
- 👤 Yasuyoshi Watanabe
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 22:41
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61P; A61P25/00; A61P25/18; A61P43/00
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
63 words
A method for ameliorating disorder of infantile autism, wherein an autistic child receives a pharmaceutical composition comprising a compound of the formula: ##STR4## (wherein R is ##STR5## or a salt thereof as an effective ingredient, at a dose wherein the amount of the effective ingredient received is in the range of 0.1 to 50 mg/kg body weight/day together with a pharmaceutically acceptable carrier.
Claim 2
Independent Claim
63 words
A method for ameliorating disorder of infantile autism, wherein an autistic child receives a pharmaceutical composition comprising a compound of the formula: ##STR4## (wherein R is ##STR5## or a salt thereof as an effective ingredient, at a dose wherein the amount of the effective ingredient received is in the range of 0.1 to 50 mg/kg body weight/day together with a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
28 words
A method according to claim 1, wherein the pharmaceutical composition further contains an anti-oxydizing agent selected from the group comprising ascorbic acid, N-acetylcysteine, L-cysteine, dl-α-tocopherol and natural tocopherol.
Claim 4
Dependent Claim
25 words
A method according to claim 1, wherein the amount of the effective ingredient received is in the range of 0.5 to 10 mg/kg body weight/day.
Claim 5
Dependent Claim
10 words
A method according to claim 1, wherein R is ##STR6##
Claim 6
Dependent Claim
12 words
A method according to claim 1, wherein the effective ingredient is L-erythro-5,6,7,8-tetrahydrobiopterin.
References Cited (Backward Citations)
US4665182A
Cited
US4701455A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-10-18 | 1992-04-18 | 1992-10-18 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-10-18 | 1996-04-18 | 1996-10-18 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-10-18 | 2000-04-18 | 2000-10-18 | $7700.00 | Window Closed / Lapsed |